News Agency
The Times

X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor - licenced to Norgine for commercialisation in Europe.

  • Written by PR Newswire
X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor - licenced to Norgine for commercialisation in Europe.

LONDON, Jan. 25, 2025 /PRNewswire/ -- Following the licensing agreement with X4 Pharmaceuticals, Norgine is pleased to see the announcement from X4 today that their Marketing Authorization Application (MAA) for mavorixafor for the treatment of WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis), a rare primary...

Read more: X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for...

How Australian Businesses Can Prepare Their Websites for AI-Powered Search Results

Search is changing rapidly. While traditional search engines remain a major source of website traffic, customers are increasingly using AI-powered platforms to discover information, compare businesses and make purchasing decisions. For Australian businesses, this shift creates a new challenge: ensuring... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion